Axa decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 90,886 shares of the company’s stock after selling 3,452 shares during the quarter. Axa owned approximately 0.10% of Neurocrine Biosciences worth $4,181,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NBIX. Capstone Asset Management Co. bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth $214,000. Wells Fargo & Company MN grew its stake in shares of Neurocrine Biosciences by 143.9% during the 1st quarter. Wells Fargo & Company MN now owns 297,122 shares of the company’s stock worth $12,864,000 after acquiring an additional 175,292 shares during the period. Canada Pension Plan Investment Board grew its stake in shares of Neurocrine Biosciences by 41.0% during the 1st quarter. Canada Pension Plan Investment Board now owns 16,500 shares of the company’s stock worth $714,000 after acquiring an additional 4,800 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Neurocrine Biosciences by 14.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 14,665 shares of the company’s stock worth $635,000 after acquiring an additional 1,890 shares during the period. Finally, Swiss National Bank grew its stake in shares of Neurocrine Biosciences by 0.7% during the 1st quarter. Swiss National Bank now owns 143,600 shares of the company’s stock worth $6,218,000 after acquiring an additional 1,000 shares during the period.

TRADEMARK VIOLATION WARNING: “Axa Cuts Stake in Neurocrine Biosciences, Inc. (NBIX)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/18/axa-cuts-stake-in-neurocrine-biosciences-inc-nbix.html.

In other news, insider Haig P. Bozigian sold 26,250 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the transaction, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $436,700.00. Following the completion of the transaction, the insider now directly owns 57,707 shares of the company’s stock, valued at approximately $2,885,350. The disclosure for this sale can be found here. In the last 90 days, insiders sold 125,655 shares of company stock valued at $7,018,148. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 56.71 on Monday. The company’s market cap is $5.00 billion. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $60.00. The firm has a 50-day moving average price of $53.95 and a 200 day moving average price of $48.92.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period last year, the firm posted ($0.46) EPS. Analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. ValuEngine upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Neurocrine Biosciences in a research note on Sunday. Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Thursday, August 24th. Finally, Cowen and Company reiterated an “outperform” rating and set a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $68.25.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.